To date, only non-optimized herbal cannabis preparations are employed for cancer treatment outside of conventional medical care. Cannabinoid based pharmaceutical agents are not yet available to oncologists for clinical cancer treatment.
Our lead oncology product is a topical compound that addresses metastatic breast cancer and associated metastatic pain.
- 15% of all cancer cases diagnosed are breast cancer.
- If a woman’s breast cancer becomes fatal, it is because it became metastatic, meaning it spread through the body.
- 1 in 8 women will be diagnosed with breast cancer in the US and Canada and 1 in 3 of those will become metastatic.
Our Oncology Program Aims to:
Improve the survival of metastatic breast cancer patients by inducing tumor regression
Improve overall quality of life through effective pain management
We are not only optimizing the cannabinoid composition against metastatic breast cancer, we are also optimizing the drug delivery system to ensure patients can be treated effectively.
Medical cannabis preparations are not always effective solutions for cancer and cancer pain because:
The cannabinoid composition has not been optimized to treat the particular cancer type
Full therapeutic doses of cannabinoids do not effectively reach tumors and metastases
Metastatic Breast Cancer Pain Facts:
Much of the pain involved in metastatic breast cancer is due to the metastatic tumors themselves.
A tumor can injure nerves or put pressure on healthy tissues in the body, causing pain.
The pain is often felt as a sharp, tingling, burning or shooting feeling, fitting the symptoms of neuropathic pain.
Metastatic breast cancer can also cause back, bone or joint pain that does not go away.
Andira’s Oncology Program incorporates sophisticated research techniques to elucidate the precise cannabinoid compositions that are optimum for metastatic breast cancer using live, patient-derived tumors.
Andira also uses enhanced transdermal drug delivery technology to ensure therapeutic cannabinoid levels are attained within metastatic tumors. The use of SPECT/CT imaging furthers allows us to fine-tune our delivery system by measuring cannabinoid dosages that reach tumors. In other words, we are not only optimizing the cannabinoid composition against metastatic breast cancer, we are also optimizing the delivery system to ensure patients can be treated effectively.